SKINVISIBLE Business Summary

Skinvisible, Inc. (SKVI) is a pharmaceutical research and development firm that generates revenue primarily through the out-licensing of its patented Invisicare® polymer delivery technology, securing upfront fees, milestone payments, and recurring royalties. The company’s primary business segments are focused on dermatology, rare skin disorders, and a high-growth transdermal obesity pipeline targeting the metabolic health market with needle-free GLP-1 and SGLT-2 delivery solutions. Skinvisible competes with specialized biotechnology and drug delivery firms such as Revance Therapeutics, Sutro Biopharma, and AXIL Brands. Within the competitive landscape, Skinvisible differentiates itself as a specialized technology enabler that optimizes the pharmacokinetic profiles of existing active ingredients, providing a low-overhead, high-margin alternative to traditional drug development for its global licensing partners. The company is led by Founder, President, and CEO Terry Howlett, who has directed Skinvisible’s strategic vision and capital formation since 1998, leveraging over three decades of entrepreneurial experience in the life sciences sector. The executive team includes Doreen McMorran, Vice President of Business Development, who oversees global out-licensing and research-driven growth strategies with over 25 years of pharmaceutical industry experience, and James A. Roszell, PhD, Head of Research & Development, a chemist with 35 years of expertise in formulation and the primary architect of the Invisicare platform. While the company operates with a lean internal structure, its market presence is amplified through strategic partnerships, most notably with Quoin Pharmaceuticals for the Phase 3 development of QRX003 and Ovation Science for cannabinoid-based obesity therapies. Terry Howlett remains the company’s primary individual shareholder, maintaining a centralized leadership approach as both CEO and CFO.